Cargando…

Who will benefit more from maintenance therapy of metastatic colorectal cancer?

Whether there is a difference in the efficacy of maintenance treatment for metastatic colorectal cancer (mCRC) between patients who achieve complete response (CR)/partial response (PR) and those with stable disease (SD) after induction treatment is controversial. PubMed, Cochrane Systematic Reviews,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Mingyi, Fu, Lingyu, Zhang, Jingdong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5844763/ https://www.ncbi.nlm.nih.gov/pubmed/29552327 http://dx.doi.org/10.18632/oncotarget.23549

Ejemplares similares

Angiogenesis in metastatic colorectal cancer and the benefits of targeted therapy
por: Sun, Weijing
Publicado: (2012)

Effect of RAS status on anti-EGFR monoclonal antibodies + 5-FU infusion-based chemotherapy in first-line treatment of metastatic colorectal cancer: A meta-analysis
por: Zhou, Mingyi, et al.
Publicado: (2016)

First-Line Maintenance Treatment in Metastatic Colorectal Cancer (mCRC): Quality and Clinical Benefit Overview
por: Martín-Richard, Marta, et al.
Publicado: (2021)

Negative Hyperselection of Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy
por: Morano, Federica, et al.
Publicado: (2019)

Metastatic Colorectal Cancer in the Era of Personalized Medicine: A More Tailored Approach to Systemic Therapy
por: Yu, Irene S., et al.
Publicado: (2018)

Efficacy and safety of bevacizumab-based maintenance therapy in metastatic colorectal cancer: A meta-analysis
por: Ma, Hongbo, et al.
Publicado: (2019)

Expert consensus on maintenance treatment for metastatic colorectal cancer in China
por: Xu, Rui-Hua, et al.
Publicado: (2016)

Is FOLFOXIRI alone or combined with targeted therapy administered as first-line treatment a reasonable choice for most patients with mCRC? Systematic review and network meta-analysis
por: Zhou, Mingyi, et al.
Publicado: (2017)

Bevacizumab in the therapy for refractory metastatic colorectal cancer
por: Mulcahy, Mary F
Publicado: (2008)

Role of targeted therapy in metastatic colorectal cancer
por: Ohhara, Yoshihito, et al.
Publicado: (2016)

Current Targeted Therapy for Metastatic Colorectal Cancer
por: Ohishi, Tomokazu, et al.
Publicado: (2023)

Rechallenge and maintenance therapy using cetuximab and chemotherapy administered to a patient with metastatic colorectal cancer
por: Ma, Jian, et al.
Publicado: (2017)

Lipid-lowering therapy: who can benefit?
por: Lewis, Sandra J
Publicado: (2011)

Immunotherapies and Targeted Therapies in the Treatment of Metastatic Colorectal Cancer
por: Rawla, Prashanth, et al.
Publicado: (2019)

Targeting Metastatic Colorectal Cancer with Immune Oncological Therapies
por: Galbraith, Norman J., et al.
Publicado: (2021)

New developments in targeted therapy for metastatic colorectal cancer
por: Wong, Ambrose H. N., et al.
Publicado: (2023)

Strategic Insight into the Combination Therapies for Metastatic Colorectal Cancer
por: Kano, Yoshihito, et al.
Publicado: (2023)

Maintenance therapies in metastatic pancreatic cancer: present and future with a focus on PARP inhibitors
por: Hammel, Pascal, et al.
Publicado: (2020)

Distinguishing Patients With Distant Metastatic Differentiated Thyroid Cancer Who Biochemically Benefit From Next Radioiodine Treatment
por: Sa, Ri, et al.
Publicado: (2020)

Safety profiles of current antiangiogenic therapies for metastatic colorectal cancer
por: Fuloria, Jyotsna
Publicado: (2012)

Metastatic Colorectal Cancer. First Line Therapy for Unresectable Disease
por: Aparicio, Jorge, et al.
Publicado: (2020)

Who Will Benefit from Charged-Particle Therapy?
por: Kim, Kyung Su, et al.
Publicado: (2021)

Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer
por: Marmorino, Federica, et al.
Publicado: (2017)

Primary Tumor Sidedness Predicts Bevacizumab Benefit in Metastatic Colorectal Cancer Patients
por: You, Xia-Hong, et al.
Publicado: (2019)

The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer
por: Ward, S E, et al.
Publicado: (2006)

The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer
por: Almond, J, et al.
Publicado: (2007)

Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies
por: Zhou, Jing, et al.
Publicado: (2021)

Capecitabine maintenance therapy in patients with recurrent or metastatic breast cancer
por: Si, W., et al.
Publicado: (2013)

Cetuximab retreatment in patients with metastatic colorectal cancer who exhibited a clinical benefit in response to prior cetuximab: A retrospective study
por: Tanioka, Hiroaki, et al.
Publicado: (2018)

Patients with metastatic renal cell carcinoma who receive immune-targeted therapy may derive survival benefit from nephrectomy
por: Dong, Hanzhi, et al.
Publicado: (2023)

Potential prognostic factors for predicting the chemotherapeutic outcomes and prognosis of patients with metastatic colorectal cancer
por: Zhang, Liqun, et al.
Publicado: (2019)

Smokers or non-smokers: who benefits more from immune checkpoint inhibitors in treatment of malignancies? An up-to-date meta-analysis
por: Mo, Jiahang, et al.
Publicado: (2020)

Breast Cancer Patients: Who Would Benefit from Neoadjuvant Chemotherapies?
por: Yao, Liqin, et al.
Publicado: (2022)

Who Benefits from Chronic Opioid Therapy? Rethinking the Question of Opioid Misuse Risk
por: Huber, Elizabeth, et al.
Publicado: (2016)

Efficacy and safety of metronomic chemotherapy in maintenance therapy for metastatic colorectal cancer: A systematic review of randomized controlled trials
por: Chen, Li, et al.
Publicado: (2022)

Metastatic colorectal cancer-prolonging overall survival with targeted therapies
por: Dattatreya, Satya
Publicado: (2013)

Advances of Targeted Therapy in Treatment of Unresectable Metastatic Colorectal Cancer
por: Lee, Suk-young, et al.
Publicado: (2016)

Emerging combination therapies for metastatic colorectal cancer – impact of trifluridine/tipiracil
por: Puthiamadathil, Jeevan M, et al.
Publicado: (2017)

Relationship between hypoxia and response to antiangiogenic therapy in metastatic colorectal cancer
por: Ulivi, Paola, et al.
Publicado: (2016)

Biomarker-Guided Anti-EGFR Rechallenge Therapy in Metastatic Colorectal Cancer
por: Ciardiello, Davide, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3al7gpgeano303nv98bt0g7o2a